Publications
- Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining2021 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Physical Education and Sport
- Sensitivity and reliability of DNA-based mutation analysis by allele-specific digital PCR to follow resistant BCR-ABL1-positive cells2021 | First Faculty of Medicine
- Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target2016 | First Faculty of Medicine, Faculty of Science
- Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase2015 | First Faculty of Medicine
- Exosomes released by imatinib-resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib-sensitive cells in the presence of imatinib2021 | First Faculty of Medicine, Faculty of Science, Central Library of Charles University
- Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission2020 | First Faculty of Medicine, Second Faculty of Medicine
- BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.2018 | First Faculty of Medicine, Central Library of Charles University
- BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia2018 | First Faculty of Medicine, Central Library of Charles University
- Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment2017 | First Faculty of Medicine, Faculty of Science, Faculty of Medicine in Hradec Králové
- Interferon-alpha Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients2016 | First Faculty of Medicine, Faculty of Science, Third Faculty of Medicine
Loading network view...